Fig. 2: Survival after CD19 donor-derived CAR-T cell treatment of relapsed B-ALL after an allotransplant.
From: Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
a 1-year EFS; b 1-year survival; c 1-year CIR in subjects with a complete histological remission without a second transplant; d, e 1-year EFS and survival in subjects with a complete histological remission without a second transplant. EFS event-free survival, CIR cumulative incidence of relapse.
